Carastock.

Overview. Founded in 2004 with headquarters in Connecticut (84 employees), Cara Therapeutics currently sports an enterprise value of ~$350M and Q2 cash position of $204M providing them operational ...Cara Therapeutics Inc Cara Therapeutics Inc CARA Morningstar Rating Unlock Stock XNAS Rating as of Nov 29, 2023 Summary Chart News Sustainability Trailing Returns Financials Valuation $0.96 −0.02...Cara Therapeutics (CARA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.Read more about CARA stock here. Cara Therapeutics's financial history has been pretty bad. The company has only turned a profit in one of the past nine years. Read more about CARA stock here.

13 Nov 2023. Forward dividend & yield. N/A (N/A) Ex-dividend date. N/A. 1y target est. 10.29. Press Releases. Find the latest Cara Therapeutics, Inc. (CARA) stock quote, history, news and other vital information to help you with your stock trading and investing.Cara Therapeutics Inc’s ( CARA) price is currently down 49.02% so far this month. During the month of March, Cara Therapeutics Inc’s stock price has reached a high of $10.39 and a low of $5.17. Over the last year, Cara Therapeutics Inc has hit prices as high as $13.97 and as low as $5.24. Year to date, Cara Therapeutics Inc’s stock is ...Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with …

Mar 13, 2023 · Cara Therapeutics' Q4 earnings EPS loss was $0.56 per share. Read why I am looking to quickly book some profits in CARA stock.

Cara Therapeutics Inc (CARA) stock is trading at $5.05 as of 2:41 PM on Friday, Mar 31, an increase of $0.16, or 3.27% from the previous closing price of $4.89. The stock has traded between $4.90 and $5.06 so far today. Volume today is light. So far 469,000 shares have traded compared to average volume of 834,454 shares.Cara Therapeutics (CARA) (Delayed Data from NSDQ) $1.10 USD +0.01 (0.92%) Updated Nov 17, 2023 03:59 PM ET After-Market: $1.11 +0.01 (0.91%) 7:58 PM ET Add to portfolio Zacks Rank: 4-Sell 4 Style...AXSM Vs CARA: Stock comparison by Artificial Intelligence. Which is a better buy? Make smart data-driven investment decisions and get unique insights. Start now and save 50% for the first 3 months save 50% for the first 3 months. Ticker. Company. Your search produced no matches. We currently support US stocks and STOXX Europe 600 …Embraer S.A. 16.28. -0.04. -0.25%. In the modern age, people are ready to get excited about flying car industry stocks. Excitement continues to build around flying car stocks following recent ...

During the previous two years, 166 institutional investors and hedge funds held shares of Cara Therapeutics. The most heavily invested institutionals were Vanguard Group Inc. ($30.96M), Disciplined Growth Investors Inc. MN ($15.91M), Chescapmanager LLC ($10.59M), BlackRock Inc. ($10.48M), Farallon Capital Management LLC ($9.80M), …

Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate …

May 25, 2023 · Simply Wall St. May 25, 2023 at 6:40 AM · 3 min read. You may think that with a price-to-sales (or "P/S") ratio of 4.4x Cara Therapeutics, Inc. ( NASDAQ:CARA) is a stock to potentially avoid ... Sector Industry Market Cap Revenue; Medical: Medical - Biomedical and Genetics: $0.058B: $0.042B: Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain.Sector Industry Market Cap Revenue; Medical: Medical - Biomedical and Genetics: $0.058B: $0.042B: Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain.When is Cara Therapeutics's earnings date? Cara Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 4th, 2024 based off last year's report dates. Learn more on …Dec 1, 2023 · According to the issued ratings of 6 analysts in the last year, the consensus rating for Cara Therapeutics stock is Moderate Buy based on the current 1 sell rating, 1 hold rating and 4 buy ratings for CARA. The average twelve-month price prediction for Cara Therapeutics is $15.86 with a high price target of $25.00 and a low price target of $4.00. Where the stock market will trade today based on Dow Jones Industrial Average, S&P 500 and Nasdaq-100 futures and implied open premarket values. Commodities, currencies and global indexes also shown.Following the downgrade, the current consensus from Cara Therapeutics' eight analysts is for revenues of US$53m in 2023 which - if met - would reflect a sizeable 27% increase on its sales over the ...

The above table shows the PS ratio for CARA vs its peers. Here we also display the market cap and forecasted growth for additional consideration. Price-To-Sales vs Peers: CARA is good value based on its Price-To-Sales Ratio (2.8x) compared to the peer average (7.9x).CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs).Future criteria checks 2/6. Cara Therapeutics is forecast to grow earnings and revenue by 10.7% and 39.6% per annum respectively. EPS is expected to grow by 27.7% per annum. Return on equity is forecast to be -187% in 3 years.Complete Cara Therapeutics Inc. stock information by Barron's. View real-time CARA stock price and news, along with industry-best analysis. View Cara Therapeutics, Inc CARA investment & stock information. Get the latest Cara Therapeutics, Inc CARA detailed stock quotes, stock data, Real-Time ECN ...

Get the latest news and real-time alerts from Cara Therapeutics, Inc. (CARA) stock at Seeking Alpha.Complete Cara Therapeutics Inc. stock information by Barron's. View real-time CARA stock price and news, along with industry-best analysis.

Over the last four quarters, the company has surpassed consensus EPS estimates two times. Cara, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $3.26 ...Find out all the key statistics for Cara Therapeutics, Inc. (CARA), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.Stock opname adalah aktivitas perhitungan jumlah stok barang atau produk yang menumpuk di gudang atau di toko sebelum barang tersebut. Yuk baca detailnya!Analyst Forecast. According to 8 analysts, the average rating for CARA stock is "Strong Buy." The 12-month stock price forecast is $15.13, which is an increase of 1,472.28% from the latest price.Nov 22, 2023 · Future criteria checks 2/6. Cara Therapeutics is forecast to grow earnings and revenue by 10.7% and 39.6% per annum respectively. EPS is expected to grow by 27.7% per annum. Return on equity is forecast to be -187% in 3 years. Cara Therapeutics Inc’s ( CARA) price is currently down 49.02% so far this month. During the month of March, Cara Therapeutics Inc’s stock price has reached a high of $10.39 and a low of $5.17. Over the last year, Cara Therapeutics Inc has hit prices as high as $13.97 and as low as $5.24. Year to date, Cara Therapeutics Inc’s stock is ...Nov 27, 2023 · It's typically categorized as a valuation metric and is most often quoted as Cash Flow per Share and as a Price to Cash flow ratio. In this case, it's the cash flow growth that's being looked at ... Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults ...Cara Therapeutics, Inc. ( NASDAQ:CARA ) shareholders will have a reason to smile today, with the analysts making... Find the latest Cara Therapeutics, Inc. (CARA) stock quote, history, news and other vital information to help you with your stock trading and investing.Cara Therapeutics Inc Follow Share $1.06 After Hours: $1.02 (3.77%) -0.040 Closed: Dec 1, 7:55:45 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Adicet Bio Inc $1.23 ACET4.24% Tilray Brands...

Mar 13, 2023 · Cara Therapeutics' Q4 earnings EPS loss was $0.56 per share. Read why I am looking to quickly book some profits in CARA stock.

According to our current CARA stock forecast, the value of CARA Therapeutics shares will drop by -19.87% and reach $ 0.746314 per share by December 3, 2023. According to our technical indicators, the current sentiment is Bearish while the Fear & Greed Index is showing 39 (Fear).

26 thg 3, 2023 ... Tips Cara Stock Opname Efisien untuk Hasil yang Akurat · Hal yang Perlu Dipersiapkan Sebelum Membuat Stock Opname · Pelaksanaan Stock Opname.Mar 29, 2023 · What's Happening with CARA Stock Today. Cara Therapeutics Inc (CARA) stock is higher by 2.07% while the S&P 500 is higher by 1.41% as of 3:38 PM on Wednesday, Mar 29. CARA is higher by $0.10 from the previous closing price of $4.94 on volume of 309,020 shares. Over the past year the S&P 500 is down -13.05% while CARA has fallen -58.65%. 26 thg 3, 2023 ... Tips Cara Stock Opname Efisien untuk Hasil yang Akurat · Hal yang Perlu Dipersiapkan Sebelum Membuat Stock Opname · Pelaksanaan Stock Opname.Sep 13, 2023 · What's Happening with CARA Stock Today Cara Therapeutics Inc (CARA) stock has gained 5.52% while the S&P 500 has gained 0.24% as of 12:13 PM on Wednesday, Sep 13. CARA has gained $0.10 from the previous closing price of $1.72 on volume of 537,920 shares. Over the past year the S&P 500 has risen 13.73% while CARA is lower by -82.48%. CARA stock was up 2.8% as of Tuesday afternoon. On the date of publication, Nick Clarkson did not have (either directly or indirectly) any positions in the securities mentioned in this article.Earnings date. 13 Nov 2023. Forward dividend & yield. N/A (N/A) Ex-dividend date. N/A. 1y target est. 10.29. Find the latest Cara Therapeutics, Inc. (CARA) stock quote, history, news and other vital information to help you with your stock trading and investing.Stock analysis for Cara Therapeutics Inc (CARA:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Stock opname adalah aktivitas perhitungan jumlah stok barang atau produk yang menumpuk di gudang atau di toko sebelum barang tersebut. Yuk baca detailnya!In comparison, Cara's annual 2018 revenue was $13.4 million and its market cap is $747 million. From a clinical perspective, the results are still pretty strong for Korsuva despite this recent ...Overview. Founded in 2004 with headquarters in Connecticut (84 employees), Cara Therapeutics currently sports an enterprise value of ~$350M and Q2 cash position of $204M providing them operational ...Who is on Cara Therapeutics's Insider Roster? The list of insiders at Cara Therapeutics includes Christopher Posner, Derek T Chalmers, Frederique Ph.D. Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion, and Thomas Charles Reilly. Learn more on insiders at CARA.

Dec 1, 2023 · View Cara Therapeutics, Inc CARA investment & stock information. Get the latest Cara Therapeutics, Inc CARA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Based on 2 Wall Street analysts offering 12 month price targets for Cara Therapeutics in the last 3 months. The average price target is $4.00 with a high ...Cara Therapeutics Inc (NASDAQ: CARA) shares dive after as investors react to topline results from its KARE Phase 2 trial evaluating oral Korsuva (difelikefalin tablets) for the treatment of ...Feb 12, 2014 · Post #2,000. Item 8.01 Other Information. As previously disclosed, on August 23, 2021, Cara Therapeutics, Inc. (“Cara”) received approval of its New Drug Application for KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients from the U.S. Food and Drug Administration (the “Approval Milestone”). Instagram:https://instagram. tulip bulb bubblebest small cap index fundtarget affirmcarvana stok Search from 81 Kuih Cara stock photos, pictures and royalty-free images from iStock. Find high-quality stock photos that you won't find anywhere else. best rv loans for good credithow to buy an nft Find the latest Cara Therapeutics, Inc. (CARA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. nasdaq trin Interactive Chart for Cara Therapeutics, Inc. (CARA), analyze all the data with a huge range of indicators.Download Calvo se sorprende, manos en la cara Stock Photo and explore similar images at Adobe Stock.Embraer S.A. 16.28. -0.04. -0.25%. In the modern age, people are ready to get excited about flying car industry stocks. Excitement continues to build around flying car stocks following recent ...